Clinical Practice for Nuclear Medicine Therapy; Part 1

DOI Web Site 1 Citations 30 References Open Access
  • MIYAJI Noriaki
    Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research
  • MAEDA Takamasa
    QST Hospital, National Institutes for Quantum Science and Technology
  • UKON Naoyuki
    Advanced Clinical Research Center, Fukushima Medical University
  • YONEYAMA Hiroto
    Department of Radiological Technology, Kanazawa University Hospital
  • YAMASHITA Kosuke
    Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research
  • HANAOKA Kohei
    Institute of Advanced Clinical Medicine, Kindai University
  • IIMORI Takashi
    Department of Radiology, Chiba University Hospital

Bibliographic Information

Other Title
  • 核医学治療の医療利用（1）
  • —Developments to Date and the Role of Radiological Technology—
  • ̶これまでの展開と放射線技術の役割̶

Description

<p>Nuclear medicine therapy is the treatment method that delivers radiation from inside the lesion where the therapeutic agent has accumulated. This can be performed minimally invasively with high antitumor efficacy against metastatic lesions throughout the body. In 2021, Lu-177 DOTATATE for neuroendocrine tumors and I-131 MIBG for malignant pheochromocytoma were approved by insurance in Japan. In addition to conventional I-131 therapy, novel radionuclides such as Lu-177 and Ra-223 are changing the current status of nuclear medicine therapy. In addition, new therapeutic radionuclides, the alphaemitting radionuclide At-211 and Ac-225, beta-emitting radionuclides Cu-64 and Cu-67, can be produced at several facilities in Japan. With the advent of new therapeutic agents, the laws governing their treatment are being revised to reflect current conditions. On the clinical side, the combination of nuclear medicine therapy and diagnostic imaging, Radio-theranostics, is being implemented more frequently than ever before. In addition, a therapeutic agent for prostate cancer, Lu-177 PSMA, was approved by the FDA. In the immediate future, this is expected to further increase the clinical use of nuclear medicine agents by Radio-theranostics.</p>

Journal

Citations (1)*help

See more

References(30)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top